CN112166125A - 全人源的抗lag-3抗体及其应用 - Google Patents
全人源的抗lag-3抗体及其应用 Download PDFInfo
- Publication number
- CN112166125A CN112166125A CN201980035403.0A CN201980035403A CN112166125A CN 112166125 A CN112166125 A CN 112166125A CN 201980035403 A CN201980035403 A CN 201980035403A CN 112166125 A CN112166125 A CN 112166125A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- antibody
- amino acid
- lag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
提供的是特异性结合LAG‑3的抗体和抗体片段,以及含有所述抗体或抗体片段的组合物。还提供了编码所述抗体或其抗体片段的核酸及包含其的宿主细胞,以及其治疗和诊断用途。
Description
PCT国内申请,说明书已公开。
Claims (20)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810629554.6A CN110615840A (zh) | 2018-06-19 | 2018-06-19 | 全人源的抗lag-3抗体及其应用 |
CN2018106295546 | 2018-06-19 | ||
PCT/CN2019/091749 WO2019242619A1 (zh) | 2018-06-19 | 2019-06-18 | 全人源的抗lag-3抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112166125A true CN112166125A (zh) | 2021-01-01 |
CN112166125B CN112166125B (zh) | 2022-09-27 |
Family
ID=68920063
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810629554.6A Pending CN110615840A (zh) | 2018-06-19 | 2018-06-19 | 全人源的抗lag-3抗体及其应用 |
CN201980035403.0A Active CN112166125B (zh) | 2018-06-19 | 2019-06-18 | 全人源的抗lag-3抗体及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810629554.6A Pending CN110615840A (zh) | 2018-06-19 | 2018-06-19 | 全人源的抗lag-3抗体及其应用 |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN110615840A (zh) |
TW (1) | TWI721457B (zh) |
WO (1) | WO2019242619A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113348182B (zh) * | 2019-12-30 | 2022-07-12 | 上海海路生物技术有限公司 | Lag-3抗体及其医药用途 |
CN114907478A (zh) * | 2021-02-08 | 2022-08-16 | 迈威(上海)生物科技股份有限公司 | 结合lag-3的抗体及其用途 |
CN113603779B (zh) * | 2021-08-18 | 2023-06-02 | 深圳市元谷生物科技有限公司 | 一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途 |
MX2024003936A (es) * | 2021-09-29 | 2024-06-28 | Akeso Biopharma Inc | Anticuerpo anti-lag3, composicion farmaceutica y uso. |
TW202334218A (zh) * | 2021-11-01 | 2023-09-01 | 中國大陸商科望(蘇州)生物醫藥科技有限公司 | 新型抗lag3抗體 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102176921A (zh) * | 2008-08-11 | 2011-09-07 | 梅达雷克斯股份有限公司 | 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途 |
TW201800419A (zh) * | 2016-06-23 | 2018-01-01 | 江蘇恆瑞醫藥股份有限公司 | Lag-3抗體、其抗原結合片段及其醫藥用途 |
WO2018069500A2 (en) * | 2016-10-13 | 2018-04-19 | Symphogen A/S | Anti-lag-3 antibodies and compositions |
US20180127496A1 (en) * | 2015-02-03 | 2018-05-10 | Anaptysbio, Inc. | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
NZ711355A (en) * | 2013-03-15 | 2020-06-26 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
-
2018
- 2018-06-19 CN CN201810629554.6A patent/CN110615840A/zh active Pending
-
2019
- 2019-06-18 CN CN201980035403.0A patent/CN112166125B/zh active Active
- 2019-06-18 WO PCT/CN2019/091749 patent/WO2019242619A1/zh active Application Filing
- 2019-06-18 TW TW108121093A patent/TWI721457B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102176921A (zh) * | 2008-08-11 | 2011-09-07 | 梅达雷克斯股份有限公司 | 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途 |
US20180127496A1 (en) * | 2015-02-03 | 2018-05-10 | Anaptysbio, Inc. | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
TW201800419A (zh) * | 2016-06-23 | 2018-01-01 | 江蘇恆瑞醫藥股份有限公司 | Lag-3抗體、其抗原結合片段及其醫藥用途 |
WO2018069500A2 (en) * | 2016-10-13 | 2018-04-19 | Symphogen A/S | Anti-lag-3 antibodies and compositions |
Non-Patent Citations (3)
Title |
---|
HE, YY; RIVARD, CJ; HIRSCH, FR: "Lymphocyte-activation gene-3, an important immune checkpoint in cancer", 《CANCER SCIENCE》 * |
KNAUS, HA等: "Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia", 《CURRENT DRUG TARGETS》 * |
OK, CY等: "Checkpoint inhibitors in hematological malignancies", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019242619A1 (zh) | 2019-12-26 |
CN110615840A (zh) | 2019-12-27 |
TW202016143A (zh) | 2020-05-01 |
TWI721457B (zh) | 2021-03-11 |
CN112166125B (zh) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112135626B (zh) | 抗tigit抗体及其用途 | |
US20230192840A1 (en) | Antibody and use thereof | |
KR101782487B1 (ko) | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 | |
CN112166125B (zh) | 全人源的抗lag-3抗体及其应用 | |
WO2020151762A1 (zh) | 新型双特异性抗体分子以及同时结合pd-l1和lag-3的双特异性抗体 | |
CN114181310B (zh) | 抗tigit抗体、其药物组合物及用途 | |
WO2022068810A1 (zh) | 抗Claudin18.2和CD3的双特异性抗体以及其用途 | |
CN114907479A (zh) | 抗cd112r抗体及其用途 | |
CN114206931A (zh) | 抗pd-1抗体及其用途 | |
WO2022135467A1 (zh) | 抗b7-h3抗体及其用途 | |
WO2021204281A1 (en) | Anti-cd47 antibody and uses thereof | |
CN112969715B (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
WO2022068809A1 (zh) | 抗cd3抗体以及其用途 | |
WO2024109657A1 (zh) | 抗ccr8抗体及其用途 | |
CA3209827A1 (en) | Anti-tnfr2 antibody and use thereof | |
JP2024509369A (ja) | 抗pd-l1抗体及びその使用 | |
TW202330026A (zh) | 用於療法之抗btn3a活化抗體及il2促效劑之組合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |